Method of preparing controlled-release preparations for biologically active materials and resulting compositions
AssigneeGS Development AB
InventorsSven Engstrom, Kare Larsson, Bjorn Lindman
Life of this patent
Estimating the term…
Abstract
A method and product for preparing a controlled-release composition are provided. The method comprises formation of a mixture containing at least one amphiphilic substance capable of forming a liquid crystalline phase, in contact with a liquid selected from the group consisting of water, glycerol, ethylene glycol, propylene glycol and mixtures thereof. The method includes a step of providing in such mixture a bioactive material.
Claims19
A composition for controlled release of selected bioactive material, said composition comprising:
- (a) a cubic liquid crystalline phase comprising a lipid bilayer and a hydrophilic domain, said lipid bilayer comprising one or more lipids selected from the group consisting of monoglycerides, phospholipids, galactolipids, and mixtures thereof, and
- (b) an effective amount of bioactive material preferentially partitioned in one of said hydrophilic domain and said lipid bilayer.
A composition for controlled release of selected bioactive material, said composition comprising:
- (a) a reversed hexagonal liquid crystalline phase having a lipid bilayer and a hydrophilic domain, said lipid bilayer comprising one or more lipids selected from the group consisting of monoglycerides, phospholipids, galactolipids, and mixtures thereof;
- and
- (b) an effective amount of selected bioactive material preferentially partitioned in one of said hydrophilic domain and said lipid bilayer.
A method of delivering a bioactive material to a patient, said method including the steps of:
- (a) administering, in vivo, a composition comprising:
- (i) a cubic liquid crystalline phase including a lipid bilayer and a hydrophilic domain, said lipid bilayer comprising one or more lipids selected from the group consisting of monoglycerides, phospholipids, galactolipids, and mixtures thereof;
- and
- (ii) an effective amount of bioactive material selectively partitioned in one of said lipid bilayer and said hydrophilic domain;
- and
- (b) allowing an effective amount of bioactive material to dissociate from said cubic liquid crystalline phase.
A method for delivering a bioactive material to a patient, said method including the steps of:
- (a) administering, in vivo, a composition comprising:
- (i) a reversed hexagonal liquid crystalline phase including a lipid bilayer and a hydrophilic domain, said lipid bilayer comprising one or more lipids selected from the group consisting of monoglycerides, phospholipids, galactolipids, and mixtures thereof;
- and
- (ii) an effective amount of bioactive material selectively partitioned in one of said lipid bilayer and said hydrophilic domain;
- and
- (b) allowing an effective amount of bioactive material to dissociate from said reversed hexagonal liquid crystalline phase.
A lipid composition for controlled release of a biologically active material which comprises:
- (a) monoolein and at least one oil in amounts necessary to form a reversed hexagonal liquid crystalline phase having a lipid bilayer and a hydrophilic domain upon contact with water;
- and
- (b) an effective amount of a bioactive material selected from the group consisting of antibiotics, proteins, steroids, vitamins and nucleic acids.
A lipid composition for controlled-release of biologically active material which comprises:
- (a) monoolein and glycerol in amounts necessary to form a reversed hexagonal liquid crystalline phase having a lipid bilayer and a hydrophilic domain upon contact with water;
- and
- (b) an effective amount of a bioactive material selected from the group consisting of antibiotics, proteins, steroids, vitamins, and nucleic acids .
Dependencies are inferred from the claim text.